Company: BWAY
Filing Date: 2025-04-22
Form Type: 20-F
Source: 0001171843-25-002347
Chunk: 83

Company: Brainsway Ltd.
Filing Date: 2025-04-22
Form: 20-F
Item: Item 5
Chunk 83
---
 research analysts.

The trading market for the ADSs may rely on the research
and reports that equity research analysts publish about us and our business. The price of the ADSs could decline if one or more securities
analysts downgrade the ADSs or if those analysts issue other unfavorable commentary or cease publishing reports about us or our business.

We may be
subject to securities litigation, which is expensive and could divert our management’s attention.

In the past, U. S.-listed companies that have experienced
volatility in the market price of their securities, including many life sciences and biotechnology companies, have been subject to securities
class action litigation. We may be the target of this type of litigation in the future. Regardless of the merits or the ultimate results
of such litigation, securities litigation brought against us could result in substantial costs and divert our management’s attention
from other business concerns, which could have a material adverse effect on our results of operations.

  47  

As a foreign
private issuer whose shares are listed on The Nasdaq Global Market, we follow certain home country corporate governance practices instead
of certain Nasdaq requirements.

As a foreign private issuer whose shares are listed
on The Nasdaq Global Market, we are permitted to follow certain home country corporate governance practices instead of certain requirements
of the rules of The Nasdaq Global Market. Although we established a quorum requirement such that the quorum for any meeting of shareholders
is two or more shareholders holding at least 33 and 1/3% of our voting rights, which complies with Nasdaq requirements, pursuant to the
“foreign private issuer exemption” we established a quorum for an adjourned meeting, if the meeting is adjourned for lack
of quorum, of two or more shareholders holding any percentage of our voting rights. We also follow Israeli corporate governance practice
in lieu of Nasdaq Marketplace Rule 5635(c), which requires shareholder approval for certain dilutive events (such as issuances that will
result in a change of control, certain transactions other than a public offering involving issuances of a 20% or greater interest in us
and certain acquisitions of the shares or assets of another company), and prior to an issuance of securities when a stock option or purchase
plan is to be established or materially amended or other equity compensation arrangement made or materially amended, pursuant to which
stock may be acquired by officers, directors, employees or consultants. Otherwise, we comply with the rules generally applicable to U. S.
domestic companies listed